MCID: RSC001
MIFTS: 60

Rosacea

Categories: Blood diseases, Skin diseases, Smell/Taste diseases

Aliases & Classifications for Rosacea

MalaCards integrated aliases for Rosacea:

Name: Rosacea 12 25 43 44 15 63 73
Erythematotelangiectatic Rosacea 25
Papulopustular Rosacea 25
Granulomatous Rosacea 25
Acne, Erythematosa 12
Phymatous Rosacea 25
Ocular Rosacea 25
Acne Roscea 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8881
ICD10 33 L71 L71.9
ICD9CM 35 695.3
MeSH 44 D012393
NCIt 50 C97136
SNOMED-CT 68 1612004
UMLS 73 C0035854

Summaries for Rosacea

MedlinePlus : 43 Rosacea is a long-term disease that affects your skin and sometimes your eyes. It causes redness and pimples. Rosacea is most common in women and people with fair skin. It most often affects middle-aged and older adults. In most cases, rosacea only affects the face. Symptoms can include Frequent redness of the face, or flushing Small, red lines under the skin Acne A swollen nose Thick skin, usually on the forehead, chin, and cheeks Red, dry, itchy eyes and sometimes vision problems No one knows what causes rosacea. You may be more likely to have it if you blush a lot or if rosacea runs in your family. Rosacea is not dangerous. There is no cure, but treatments can help. They include medicines and sometimes surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Rosacea, also known as erythematotelangiectatic rosacea, is related to psoriasis and dermatitis, atopic, and has symptoms including pruritus and exanthema. An important gene associated with Rosacea is CAMP (Cathelicidin Antimicrobial Peptide), and among its related pathways/superpathways are Human cytomegalovirus infection and Influenza A. The drugs Ivermectin and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are behavior/neurological and cardiovascular system

Genetics Home Reference : 25 Rosacea is a long-lasting (chronic) skin disease that affects the face, primarily the forehead, nose, cheeks, and chin. The signs and symptoms of rosacea vary, and they may come and go or change over time.

PubMed Health : 63 About rosacea: Red patches of skin on your face, and tiny visible blood vessels and spots – these can be quite common symptoms. They may be caused by rosacea, a common facial skin inflammation.Skin diseases can be difficult to cope with, and they often affect people’s self-confidence and wellbeing. But if you have rosacea, there is a lot you can do on your own.

Wikipedia : 76 Rosacea is a long-term skin condition that typically affects the face. It results in redness, pimples,... more...

Related Diseases for Rosacea

Diseases related to Rosacea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 269)
# Related Disease Score Top Affiliating Genes
1 psoriasis 30.3 CAMP IL6 TNF VDR
2 dermatitis, atopic 29.9 CAMP TLR2 TNF TRPV1
3 keratitis, hereditary 29.7 MMP9 TLR2 VEGFA
4 fungal keratitis 29.7 MMP8 MMP9 TLR2
5 inflammatory bowel disease 29.6 IL6 TLR2 TNF TRPV1 VDR
6 chlamydia 29.6 IL6 TLR2 TNF
7 vascular disease 29.4 IL6 MMP9 TNF VEGFA
8 rheumatoid arthritis 29.2 IL6 MMP9 TLR2 TNF VEGFA
9 granulomatous rosacea 12.6
10 rosacea conjunctivitis 12.1
11 dermatitis 10.5
12 neurofibromatosis, type ii 10.4
13 demodicidosis 10.3
14 mycobacterium marinum 10.3 CAMP TLR2
15 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.2
16 angiokeratoma circumscriptum 10.2 MMP9 VEGFA
17 adult dermatomyositis 10.2 TNF VDR
18 trench fever 10.2 TLR2 TNF
19 autoimmune inner ear disease 10.2 MMP9 TNF
20 adamantinous craniopharyngioma 10.2 MMP9 VEGFA
21 ischemic colitis 10.2 MMP9 VEGFA
22 amaurosis fugax 10.2 MMP8 MMP9
23 scleritis 10.2 MMP9 TNF
24 haemophilus influenzae 10.2 TLR2 TNF
25 kashin-beck disease 10.2 TNF VEGFA
26 congenital cytomegalovirus 10.2 TLR2 TNF
27 tendinopathy 10.1 MMP8 VEGFA
28 penicilliosis 10.1 TLR2 TNF
29 nontuberculous mycobacterial lung disease 10.1 TLR2 TNF
30 diabetic foot ulcers 10.1 IL6 MMP9
31 contact dermatitis 10.1
32 acute transverse myelitis 10.1 IL6 MMP9
33 radiation proctitis 10.1 TNF VEGFA
34 scorpion envenomation 10.1 IL6 TNF
35 mycobacterium abscessus 10.1 TLR2 TNF
36 leukomalacia 10.1 IL6 TNF
37 angioimmunoblastic lymphadenopathy with dysproteinemia 10.1 IL6 TNF
38 streptococcal toxic-shock syndrome 10.1 IL6 TNF
39 juvenile ankylosing spondylitis 10.1 IL6 TNF
40 lepromatous leprosy 10.1 TLR2 TNF VDR
41 cardiogenic shock 10.1 IL6 TNF
42 null-cell leukemia 10.1 IL6 TNF
43 parkinson disease, late-onset 10.1
44 skin disease 10.1
45 lymphoma 10.1
46 blepharitis 10.1
47 depression 10.1
48 retinitis pigmentosa 55 10.1 IL6 TNF
49 spinal disease 10.1 IL6 VEGFA
50 anca-associated vasculitis 10.1 IL6 TNF

Graphical network of the top 20 diseases related to Rosacea:



Diseases related to Rosacea

Symptoms & Phenotypes for Rosacea

UMLS symptoms related to Rosacea:


pruritus, exanthema

MGI Mouse Phenotypes related to Rosacea:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
2 cardiovascular system MP:0005385 10.2 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
3 cellular MP:0005384 10.19 CAMP GTF2IRD1 IL6 MMP9 TLR2 TNF
4 homeostasis/metabolism MP:0005376 10.19 GTF2IRD1 IL6 MMP8 MMP9 PTGDR TLR2
5 immune system MP:0005387 10.18 CAMP IL6 MMP8 MMP9 PTGDR TLR2
6 hematopoietic system MP:0005397 10.11 CAMP IL6 MMP9 PTGDR TLR2 TNF
7 integument MP:0010771 10.11 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
8 mortality/aging MP:0010768 10.06 CAMP GTF2IRD1 IL6 MMP9 PTGDR TLR2
9 digestive/alimentary MP:0005381 10 IL6 MMP9 TLR2 TNF VDR VEGFA
10 adipose tissue MP:0005375 9.97 GTF2IRD1 IL6 TLR2 TNF TRPV1
11 muscle MP:0005369 9.97 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
12 neoplasm MP:0002006 9.92 GTF2IRD1 IL6 MMP8 MMP9 TLR2 TNF
13 liver/biliary system MP:0005370 9.91 GTF2IRD1 IL6 TLR2 TNF TRPV1 VEGFA
14 nervous system MP:0003631 9.91 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
15 renal/urinary system MP:0005367 9.63 IL6 MMP9 TLR2 TRPV1 VDR VEGFA
16 respiratory system MP:0005388 9.5 GTF2IRD1 IL6 MMP9 PTGDR TLR2 TNF
17 skeleton MP:0005390 9.17 GTF2IRD1 IL6 MMP9 TLR2 TNF VDR

Drugs & Therapeutics for Rosacea

PubMedHealth treatment related to Rosacea: 63

There are a lot of creams, lotions and gels recommended for the treatment of rosacea. Creams and gels with either azelaic acid or the antibiotic metronidazole in them are used most commonly. Antibiotics can also be taken as tablets, but then the entire body is affected.

Drugs for Rosacea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 70288-86-7 6474909
2
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 564-25-0 54671203
3
Azelaic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123-99-9 2266
4
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1 443-48-1 4173
5
Pseudoephedrine Approved Phase 4,Phase 3 90-82-4 7028
6
Phenylephrine Approved Phase 4,Phase 3 59-42-7 6041
7
Oxymetazoline Approved, Investigational Phase 4,Phase 3 1491-59-4 4636
8
Ephedrine Approved Phase 4,Phase 3 299-42-3 9294
9
Sulfacetamide Approved Phase 4 144-80-9 5320
10
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
11
Aminolevulinic acid Approved Phase 4,Not Applicable 106-60-5 137
12
Timolol Approved Phase 4,Phase 1 26839-75-8 33624 5478
13 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Autonomic Agents Phase 4,Phase 3,Not Applicable
19 Respiratory System Agents Phase 4,Phase 3,Phase 1,Phase 2
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
22 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
24 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Brimonidine Tartrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 70359-46-5
27 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Vasoconstrictor Agents Phase 4,Phase 3
32 Protective Agents Phase 4,Phase 3
33 Mydriatics Phase 4,Phase 3
34 Nasal Decongestants Phase 4,Phase 3
35 Sympathomimetics Phase 4,Phase 3
36 Cardiotonic Agents Phase 4,Phase 3
37 Antirheumatic Agents Phase 4,Phase 2,Phase 1
38 Immunosuppressive Agents Phase 4,Phase 2
39 Cyclosporins Phase 4
40 Calcineurin Inhibitors Phase 4,Phase 2
41 Antifungal Agents Phase 4
42 Immunologic Factors Phase 4,Phase 2,Phase 1
43 Photosensitizing Agents Phase 4,Not Applicable
44 Adrenergic Antagonists Phase 4,Phase 1
45 Adrenergic beta-Antagonists Phase 4,Phase 1
46 Anti-Arrhythmia Agents Phase 4,Phase 1
47
Minocycline Approved, Investigational Phase 3,Phase 2,Phase 1 10118-90-8 5281021
48
Clindamycin Approved, Vet_approved Phase 2, Phase 3 18323-44-9 29029
49
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
50 tannic acid Approved Phase 3

Interventional clinical trials:

(show top 50) (show all 162)
# Name Status NCT ID Phase Drugs
1 Intense Pulsed Light as an Adjunctive to Bromonidine for the Treatment of Rosacea Unknown status NCT03053700 Phase 4 Bromonide 0.33% gel
2 Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea Completed NCT01872715 Phase 4 Oracea
3 Internet Surveys and Their Impact on Adherence for Rosacea Completed NCT03048058 Phase 4 brimonidine topical gel 0.33% & survey;brimonidine topical gel 0.33% & SOC
4 MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. Completed NCT02616250 Phase 4 Brimonidine 0.33% gel (Br);Ivermectin 1% cream (IVM)
5 Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo Completed NCT01308619 Phase 4 Doxycycline
6 Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea Completed NCT00855595 Phase 4 Azelaic acid (Finacea, BAY39-6251);Metronidazole (Metrogel);Doxycycline (Oracea)
7 Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study Completed NCT02147691 Phase 4 Azelaic acid 15%;Brimonidine 0.33%
8 Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea Completed NCT03380390 Phase 4 Oxymetazoline HCL 1.0% Cream
9 Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens Completed NCT00495313 Phase 4 doxycycline;doxycycline
10 ORCA - Oracea® for Rosacea: A Community-based Assessment Completed NCT00892281 Phase 4 doxycycline (Oracea®) 40 mg modified release as monotherapy;doxycycline (Oracea®) 40 mg modified release as add-on therapy
11 Efficacy of Topical Cyclosporin for Ocular Rosacea Completed NCT00348335 Phase 4 Cyclosporine 0.05%;Ocular lubricant
12 A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily Completed NCT00417937 Phase 4 azelaic acid 15% gel;azelaic acid 15% gel
13 Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo Completed NCT01426269 Phase 4 Doxycycline;Metronidazole;Placebo
14 Mirvaso in Use Study Completed NCT02249065 Phase 4 Brimonidine
15 Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application Completed NCT00436527 Phase 4 Metronidazole gel 1%
16 Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias Completed NCT02761174 Phase 4 Brimonidine
17 Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea Recruiting NCT03418610 Phase 4 Azelaic Acid foam 15%
18 Photodynamic Therapy for Papulopustular Rosacea Recruiting NCT02075671 Phase 4 Aminolevulinic acid topical solution 20%
19 Oracea Soolantra Association in Patients With Severe Rosacea Active, not recruiting NCT03075891 Phase 4 Ivermectin 1% cream;Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
20 Topical Timolol for the Treatment of Benign Vascular Periocular Lesions Withdrawn NCT01250457 Phase 4 topical Timolol
21 Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis Unknown status NCT02036229 Phase 3 ivermectin cream 0.5%
22 Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed NCT01318733 Phase 3 CD07805/47 gel 0.5%
23 Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea Completed NCT01555463 Phase 3 Azelaic acid foam, 15% (BAY39-6251);Vehicle foam
24 Azelaic Acid on Demodex Counts in Rosacea Completed NCT03035955 Phase 2, Phase 3 Azelaic acid
25 Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT02289352 Phase 3 Brimonidine;placebo
26 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed NCT01355458 Phase 3 CD07805/47 gel;Placebo
27 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Completed NCT01355471 Phase 3 CD07805/47 Gel;Placebo
28 A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea Completed NCT02393937 Phase 3 Reference: Metronidazole Gel 1%;Test: Metronidazole Gel 1%;Placebo Gel
29 A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea Completed NCT02120924 Phase 3 Azelaic acid
30 To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea Completed NCT03689010 Phase 3 Azelaic acid foam 15%;Finacea® (Azelaic acid Foam) 15%;Vehicle of the test product
31 A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Patients With Rosacea Completed NCT03287791 Phase 3 Azelaic acid (Finacea®) Foam;Generic Azelaic Acid Foam;Vehicle Foam
32 Phase 3 Papulopustular Rosacea Study Completed NCT01494467 Phase 3 CD5024;Azelaic acid 15% Gel
33 Phase 3 Papulopustular Rosacea Study Completed NCT01493687 Phase 3 CD5024;Azelaic acid 15% Gel
34 A Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea Completed NCT03142451 Phase 3 FMX-103
35 Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea Completed NCT02132117 Phase 3 Oxymetazoline HCL Cream 1.0%;Vehicle to Oxymetazoline HCL Cream
36 Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea Completed NCT00041977 Phase 3 doxycycline hyclate 20 mg twice daily
37 Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea Completed NCT00823901 Phase 2, Phase 3 Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel;Placebo gel
38 A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea Completed NCT02095158 Phase 3 Oxymetazoline HCL Cream 1.0%
39 An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea Completed NCT03352323 Phase 3 Oxymetazoline
40 Isotretinoin in Papular-Pustular Rosacea Completed NCT00882531 Phase 3 isotretinoin;placebo
41 CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study Completed NCT01493947 Phase 3 Ivermectin 1% cream;Metronidazole 0.75% cream
42 Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea Completed NCT01016782 Phase 3 0444
43 Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea Completed NCT01659853 Phase 3 CD07805/47 gel 0.5%/CD07805/47 Vehicle;azelaic acid gel 15%
44 A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea Completed NCT00126399 Phase 3 doxycycline
45 Clinical Endpoint Study of Ivermectin 1% Cream Completed NCT02840461 Phase 3 Ivermectin Cream, 1%;Placebo/Vehicle cream
46 Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea Completed NCT02131636 Phase 3 AGN-199201;Vehicle to AGN-199201
47 Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face Completed NCT02800148 Phase 3 Azelaic acid foam;Azelaic acid foam;Azelaic acid foam - Placebo
48 Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea Completed NCT02795117 Phase 3 Ivermectin;Ivermectin (reference);Placebo
49 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea Completed NCT01789775 Phase 3 Drug: CD07805/47 gel;CD07805/47 gel Placebo
50 Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea Completed NCT02385240 Phase 3 Brimonidine Topical Gel, 0.33 percent (Perrigo);Brimonidine Topical Gel, 0.33 percent (Reference);Placebo gel

Search NIH Clinical Center for Rosacea

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: rosacea

Genetic Tests for Rosacea

Anatomical Context for Rosacea

MalaCards organs/tissues related to Rosacea:

41
Skin, Eye, Testes, Bone, B Cells, Kidney, Small Intestine

Publications for Rosacea

Articles related to Rosacea:

(show top 50) (show all 1109)
# Title Authors Year
1
Successful treatment of erythematotelangiectatic rosacea with intense pulsed light: Report of 13 cases. ( 29952023 )
2018
2
Efficacy and Safety of Oxymetazoline Cream 1.0% for Treatment of Persistent Facial Erythema Associated With Rosacea: Findings From the 52-Week Open Label REVEAL Trial. ( 29409914 )
2018
3
In Vitro Safety Pharmacology Profiling of Topical I+-Adrenergic Agonist Treatments for Erythema of Rosacea. ( 29374829 )
2018
4
Rosacea-like demodicosis (but not primary demodicosis) and papulo pustular rosacea may beA two phenotypes of the same disease-a microbioma,therapeutic and diagnostic tools perspective. ( 29959784 )
2018
5
Frontal fibrosing alopecia and cutaneous comorbidities: A potential relationship with rosacea. ( 29447678 )
2018
6
A case report of granulomatous rosacea of the face. ( 29748691 )
2018
7
Social factors and aromatase gene expression during adult male-to-female sex change in captive leopard grouper Mycteroperca rosacea. ( 29357278 )
2018
8
Rosacea-like cutaneous localization of small lymphocytic lymphoma unmasked by high-frequency-ultrasound. ( 29790607 )
2018
9
Increased expression of IL-33 in rosacea skin and UVB-irradiated and LL-37-treated HaCaT cells. ( 29873850 )
2018
10
Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for Treatment of Persistent Facial Erythema Associated With Rosacea: Findings From the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials. ( 29409915 )
2018
11
Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0. ( 29879249 )
2018
12
Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline Recommendations. ( 29943217 )
2018
13
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial. ( 29320594 )
2018
14
Rosacea and alcohol intake. ( 29126626 )
2018
15
To test or not to test: A study examining the return rates of rosacea patients treated with a pulsed dye laser. ( 29388860 )
2018
16
Dual-Frequency Ultrasound as a New Treatment Modality for Refractory Rosacea: A Retrospective Study. ( 29746429 )
2018
17
Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study. ( 29915642 )
2018
18
Fifteen Minute Test May Save 15% or More on Rosacea Treatment. ( 29879260 )
2018
19
IL-1I+ and MMP-9 Tear Levels of Patients with Active Ocular Rosacea before and after Treatment with Systemic Azithromycin or Doxycycline. ( 29874670 )
2018
20
Assessment of rosacea symptom severity by genome-wide association study and expression analysis highlights immuno-inflammatory and skin pigmentation genes. ( 29771307 )
2018
21
Prevalence of gastrointestinal comorbidities in rosacea: Comparison of subantimicrobial, modified release doxycycline versus conventional release doxycycline. ( 29332715 )
2018
22
Allergic contact dermatitis from formaldehyde mimicking impetigo and initiating rosacea. ( 29611264 )
2018
23
Demodex and rosacea: Is there a relationship? ( 29283119 )
2018
24
Rosacea-like demodicosis and papulopustular rosacea may be two phenotypes of the same disease, and pityriasis folliculorum may be their precursor. Response to the comment of Tatu. ( 29961950 )
2018
25
Applying the phenotype approach for rosacea to practice and research. ( 29799114 )
2018
26
The Evaluation of Contact Sensitivity with Standard and Cosmetic Patch Test Series in Rosacea Patients. ( 29853742 )
2018
27
A Phase II, Randomized, Double-Blind Clinical Study Evaluating the Safety, Tolerability, and Efficacy of a Topical Minocycline Foam, FMX103, for the Treatment of Facial Papulopustular Rosacea. ( 29396702 )
2018
28
A Biologically Based Approach to Acne and Rosacea. ( 29879248 )
2018
29
Mesotherapy with Botulinum toxin for the treatment of refractory vascular and papulopustular rosacea. ( 29787842 )
2018
30
Inate immunity in rosacea. Langerhans cells, plasmacytoid dentritic cells, Toll-like receptors and inducible oxide nitric synthase (iNOS) expression in skin specimens: case-control study. ( 29330632 )
2018
31
The impact of age, sex, blepharitis, rosacea and rheumatoid arthritis on <i>Demodex</i> mite infection. ( 29593809 )
2018
32
Daily Oxymetazoline Cream Demonstrates High and Sustained Efficacy in Patients With Persistent Erythema of Rosacea Through 52 Weeks of Treatment. ( 29860043 )
2018
33
Long-term effects of intense pulsed light treatment on the ocular surface in patients with rosacea-associated meibomian gland dysfunction. ( 29958778 )
2018
34
Prescription to Over-the-Counter Switch of Metronidazole and Azelaic Acid for Treatment of Rosacea. ( 29971432 )
2018
35
Granulomatous Rosacea Versus Lupus Miliaris Disseminatus Faciei-2 Faces of Facial Granulomatous Disorder: A Clinicohistological and Molecular Study. ( 30085956 )
2018
36
The relationship between inflammatory bowel disease and rosacea over the lifespan: A meta-analysis. ( 30389397 )
2018
37
Evaluating and Optimizing the Diagnosis of Erythematotelangiectatic Rosacea. ( 29499796 )
2018
38
A Review of the Current Modalities for the Treatment of Papulopustular Rosacea. ( 29499797 )
2018
39
Medical Management of Facial Redness in Rosacea. ( 29499798 )
2018
40
Revisiting Rosacea Criteria: Where Have We Been, Where Are We Going, and How Will We Get There? ( 29499799 )
2018
41
Patient Costs Associated with Rosacea. ( 29499800 )
2018
42
Coping Mechanisms and Resources for Patients Suffering from Rosacea. ( 29499801 )
2018
43
Rosacea Pathogenesis. ( 29499802 )
2018
44
Genetic Predisposition to Rosacea. ( 29499803 )
2018
45
Validity and Reliability of a Rosacea Self-Assessment Tool. ( 29499804 )
2018
46
Measurement of Disease Severity in a Population of Rosacea Patients. ( 29499805 )
2018
47
Complexities of Rosacea. ( 29499806 )
2018
48
An update on the treatment of rosacea. ( 29507456 )
2018
49
Contact hypersensitivity in rosacea - a report on 143 cases. ( 29524258 )
2018
50
Successful therapy of ocular rosacea with topical ivermectin. ( 29527668 )
2018

Variations for Rosacea

Expression for Rosacea

Search GEO for disease gene expression data for Rosacea.

Pathways for Rosacea

Pathways related to Rosacea according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 IL6 MMP9 TLR2 TNF VEGFA
2
Show member pathways
12.63 GTF2IRD1 IL6 TLR2 TNF
3
Show member pathways
12.14 IL6 MMP9 TLR2 TNF
4
Show member pathways
12.08 IL6 TLR2 TNF
5 12.08 MMP9 TLR2 TNF VEGFA
6
Show member pathways
12.03 IL6 TLR2 TNF
7 12.02 IL6 TNF VEGFA
8 11.94 MMP9 TNF VEGFA
9
Show member pathways
11.9 IL6 TLR2 TNF
10 11.86 IL6 MMP9 TNF
11 11.81 IL6 MMP9 TNF
12
Show member pathways
11.77 IL6 MMP9 TLR2 TNF
13 11.75 IL6 TNF VEGFA
14
Show member pathways
11.74 MMP8 MMP9 TNF
15 11.72 IL6 TLR2 TNF
16 11.68 IL6 MMP9 TNF VEGFA
17 11.61 CAMP IL6 TLR2 TNF VDR
18 11.57 IL6 MMP9 TNF
19 11.51 IL6 MMP9 TNF
20 11.51 IL6 TLR2 TNF VEGFA
21 11.46 MMP9 PTGDR VEGFA
22 11.41 IL6 TLR2 TNF
23 11.32 IL6 TLR2 TNF
24 11.29 IL6 MMP9 TNF
25
Show member pathways
11.26 IL6 MMP9 TNF VEGFA
26 11.24 IL6 MMP9 TLR2 TNF VEGFA
27 11.23 IL6 TNF VDR
28 11.05 MMP9 TLR2
29 11.03 MMP9 VEGFA
30 10.97 IL6 TNF
31 10.9 IL6 TNF
32 10.74 TNF VDR

GO Terms for Rosacea

Cellular components related to Rosacea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tertiary granule lumen GO:1904724 8.8 CAMP MMP8 MMP9

Biological processes related to Rosacea according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.89 CAMP MMP8 MMP9 TLR2
2 positive regulation of apoptotic process GO:0043065 9.85 IL6 MMP9 TNF TRPV1
3 cytokine-mediated signaling pathway GO:0019221 9.81 IL6 MMP9 TNF VEGFA
4 inflammatory response GO:0006954 9.8 IL6 PTGDR TLR2 TNF TRPV1
5 positive regulation of protein phosphorylation GO:0001934 9.79 MMP9 TNF VEGFA
6 cellular response to lipopolysaccharide GO:0071222 9.77 CAMP IL6 TNF
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.76 IL6 TLR2 TNF
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.7 IL6 TNF VEGFA
9 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.65 MMP8 TLR2 TNF
10 positive regulation of nitric oxide biosynthetic process GO:0045429 9.63 MMP8 TNF TRPV1
11 positive regulation of gene expression GO:0010628 9.63 IL6 MMP8 TLR2 TNF VDR VEGFA
12 defense response to Gram-positive bacterium GO:0050830 9.62 CAMP IL6 TLR2 TNF
13 negative regulation of neurogenesis GO:0050768 9.61 IL6 TNF
14 positive regulation of protein complex assembly GO:0031334 9.61 TNF VEGFA
15 macrophage differentiation GO:0030225 9.58 MMP9 VEGFA
16 positive regulation of glial cell proliferation GO:0060252 9.57 IL6 TNF
17 negative regulation of growth of symbiont in host GO:0044130 9.56 CAMP TNF
18 negative regulation of lipid storage GO:0010888 9.54 IL6 TNF
19 positive regulation of chemokine production GO:0032722 9.54 IL6 TLR2 TNF
20 regulation of neuroinflammatory response GO:0150077 9.49 MMP8 MMP9
21 regulation of microglial cell activation GO:1903978 9.43 MMP8 TNF
22 microglial cell activation GO:0001774 9.43 TLR2 TNF TRPV1
23 positive regulation of interleukin-6 production GO:0032755 9.26 IL6 MMP8 TLR2 TNF
24 positive regulation of neuroinflammatory response GO:0150078 8.8 IL6 MMP8 TNF

Sources for Rosacea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....